Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.
Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. Zhang W, et al. Among authors: schultheis a. Pharmacogenet Genomics. 2006 Jul;16(7):475-83. doi: 10.1097/01.fpc.0000220562.67595.a5. Pharmacogenet Genomics. 2006. PMID: 16788380 Clinical Trial.
Molecular determinants of irinotecan efficacy.
Vallböhmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M, Fazzone W, Schultheis AM, Sherrod AE, Danenberg KD, Lenz HJ. Vallböhmer D, et al. Int J Cancer. 2006 Nov 15;119(10):2435-42. doi: 10.1002/ijc.22129. Int J Cancer. 2006. PMID: 16894565
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ. Zhang W, et al. J Clin Oncol. 2007 Aug 20;25(24):3712-8. doi: 10.1200/JCO.2006.08.8021. J Clin Oncol. 2007. PMID: 17704420 Clinical Trial.
Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA, Nagashima F, Chang HM, Lenz HJ. Lurje G, et al. Among authors: schultheis am. Ann Oncol. 2008 Oct;19(10):1734-41. doi: 10.1093/annonc/mdn368. Epub 2008 Jun 11. Ann Oncol. 2008. PMID: 18550579 Free PMC article.
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Kron A, Alidousty C, Scheffler M, Merkelbach-Bruse S, Seidel D, Riedel R, Ihle MA, Michels S, Nogova L, Fassunke J, Heydt C, Kron F, Ueckeroth F, Serke M, Krüger S, Grohe C, Koschel D, Benedikter J, Kaminsky B, Schaaf B, Braess J, Sebastian M, Kambartel KO, Thomas R, Zander T, Schultheis AM, Büttner R, Wolf J. Kron A, et al. Among authors: schultheis am. Ann Oncol. 2018 Oct 1;29(10):2068-2075. doi: 10.1093/annonc/mdy333. Ann Oncol. 2018. PMID: 30165392 Free PMC article.
RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers.
Lemetre C, Vieites B, Ng CK, Piscuoglio S, Schultheis AM, Marchiò C, Murali R, Lopez-García MA, Palacios JC, Jungbluth AA, Terracciano LM, Reis-Filho JS, Weigelt B. Lemetre C, et al. Among authors: schultheis am. Eur J Cancer. 2016 Sep;64:149-58. doi: 10.1016/j.ejca.2016.05.028. Epub 2016 Jul 14. Eur J Cancer. 2016. PMID: 27420608 Free PMC article.
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.
Scheffler M, Merkelbach-Bruse S, Bos M, Fassunke J, Gardizi M, Michels S, Groneck L, Schultheis AM, Malchers F, Leenders F, Kobe C, König K, Heukamp LC, Sos ML, Thomas RK, Büttner R, Wolf J. Scheffler M, et al. J Thorac Oncol. 2015 Jun;10(6):e40-3. doi: 10.1097/JTO.0000000000000503. J Thorac Oncol. 2015. PMID: 26001148 Free article. No abstract available.
114 results